# Digital Turbine, Inc.: financial statements, quarterly

APPS · Nasdaq · CIK 317788 · [Financials](/sectors/financials.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/apps.md) · [Financials](/companies/apps/financials.md) · [Filings](/companies/apps/filings.md) · [Insiders](/companies/apps/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/apps/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [143](/filings/0001628280-24-045815.md) | [143](/filings/0001628280-25-004090.md) | [112 d](/filings/0001628280-26-038115.md) | [118](/filings/0001628280-25-037888.md) | [119](/filings/0001628280-25-048946.md) | [135](/filings/0001628280-26-005047.md) | [119 d](/filings/0001628280-26-038115.md) | [131](/filings/0001628280-26-053446.md) | [140](/filings/0001628280-25-048946.md) | [151](/filings/0001628280-26-005047.md) | [143 d](/filings/0001628280-26-038115.md) | [166](/filings/0001628280-26-053446.md) |
| Cost of revenue | $m | [68.7](/filings/0001628280-24-045815.md) | [70.4](/filings/0001628280-25-004090.md) | [53.6 d](/filings/0001628280-26-038115.md) | [55.8](/filings/0001628280-25-037888.md) | [56.3](/filings/0001628280-25-048946.md) | [69.9](/filings/0001628280-26-005047.md) | [53.2 d](/filings/0001628280-26-038115.md) | [58.1](/filings/0001628280-26-053446.md) | [63.1](/filings/0001628280-25-048946.md) | [64.4](/filings/0001628280-26-005047.md) | [58.0 d](/filings/0001628280-26-038115.md) | [71.0](/filings/0001628280-26-053446.md) |
| Gross profit | $m | [74.5](/filings/0001628280-24-045815.md) | [72.3](/filings/0001628280-25-004090.md) | [58.7 d](/filings/0001628280-26-038115.md) | [62.2](/filings/0001628280-25-037888.md) | [62.4](/filings/0001628280-25-048946.md) | [64.7](/filings/0001628280-26-005047.md) | [66.0 d](/filings/0001628280-26-038115.md) | [72.8](/filings/0001628280-26-053446.md) | [77.3](/filings/0001628280-25-048946.md) | [87.0](/filings/0001628280-26-005047.md) | [84.6 d](/filings/0001628280-26-038115.md) | [94.9](/filings/0001628280-26-053446.md) |
| Research and development | $m | [14.0](/filings/0001628280-24-045815.md) | [13.0](/filings/0001628280-25-004090.md) | [11.3 d](/filings/0001628280-26-038115.md) | [10.7](/filings/0001628280-25-037888.md) | [9.4](/filings/0001628280-25-048946.md) | [10.2](/filings/0001628280-26-005047.md) | [9.1 d](/filings/0001628280-26-038115.md) | [10.1](/filings/0001628280-26-053446.md) | [11.0](/filings/0001628280-25-048946.md) | [9.9](/filings/0001628280-26-005047.md) | [9.5 d](/filings/0001628280-26-038115.md) | [10.6](/filings/0001628280-26-053446.md) |
| Operating income | $m | [(153)](/filings/0001628280-24-045815.md) | [(9.3)](/filings/0001628280-25-004090.md) | [(208) d](/filings/0001628280-26-038115.md) | [(16.1)](/filings/0001628280-25-037888.md) | [(13.5)](/filings/0001628280-25-048946.md) | [(12.8)](/filings/0001628280-26-005047.md) | [(11.7) d](/filings/0001628280-26-038115.md) | [(4.7)](/filings/0001628280-26-053446.md) | [6.5](/filings/0001628280-25-048946.md) | [21.7](/filings/0001628280-26-005047.md) | [10.5 d](/filings/0001628280-26-038115.md) | [23.1](/filings/0001628280-26-053446.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(0.7)](/filings/0001628280-24-045815.md) | [(2.8)](/filings/0001628280-25-004090.md) | [20.4 d](/filings/0001628280-26-038115.md) | [1.8](/filings/0001628280-25-037888.md) | [1.4](/filings/0001628280-25-048946.md) | [2.4](/filings/0001628280-26-005047.md) | [(1.3) d](/filings/0001628280-26-038115.md) | [(2.1)](/filings/0001628280-26-053446.md) | [1.5](/filings/0001628280-25-048946.md) | [3.2](/filings/0001628280-26-005047.md) | [3.8 d](/filings/0001628280-26-038115.md) | [2.3](/filings/0001628280-26-053446.md) |
| Net income | $m | [(161)](/filings/0001628280-24-045815.md) | [(14.1)](/filings/0001628280-25-004090.md) | [(237) d](/filings/0001628280-26-038115.md) | [(25.2)](/filings/0001628280-26-005047.md) | [(25.0)](/filings/0001628280-26-005047.md) | [(23.1)](/filings/0001628280-26-005047.md) | [(18.8) d](/filings/0001628280-26-038115.md) | [(14.1)](/filings/0001628280-26-053446.md) | [(21.4)](/filings/0001628280-26-005047.md) | [5.1](/filings/0001628280-26-005047.md) | [(7.3) d](/filings/0001628280-26-038115.md) | [(11.3)](/filings/0001628280-26-053446.md) |
| Diluted EPS | $ per share | [(1.61)](/filings/0001628280-24-045815.md) | [(0.14)](/filings/0001628280-25-004090.md) | not reported | [(0.25)](/filings/0001628280-25-037888.md) | [(0.24)](/filings/0001628280-25-048946.md) | [(0.22)](/filings/0001628280-26-005047.md) | not reported | [(0.13)](/filings/0001628280-26-053446.md) | [(0.20)](/filings/0001628280-25-048946.md) | [0.03](/filings/0001628280-26-005047.md) | not reported | [(0.09)](/filings/0001628280-26-053446.md) |
| Basic EPS | $ per share | [(1.61)](/filings/0001628280-24-045815.md) | [(0.14)](/filings/0001628280-25-004090.md) | not reported | [(0.25)](/filings/0001628280-25-037888.md) | [(0.24)](/filings/0001628280-25-048946.md) | [(0.22)](/filings/0001628280-26-005047.md) | not reported | [(0.13)](/filings/0001628280-26-053446.md) | [(0.20)](/filings/0001628280-25-048946.md) | [0.04](/filings/0001628280-26-005047.md) | not reported | [(0.09)](/filings/0001628280-26-053446.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [58.1](/filings/0001628280-24-045815.md) | [49.0](/filings/0001628280-25-004090.md) | [32.9](/filings/0001628280-26-038115.md) | [35.0](/filings/0001628280-25-037888.md) | [32.1](/filings/0001628280-25-048946.md) | [34.6](/filings/0001628280-26-005047.md) | [39.4](/filings/0001628280-26-038115.md) | [33.4](/filings/0001628280-26-053446.md) | [38.8](/filings/0001628280-25-048946.md) | [40.2](/filings/0001628280-26-005047.md) | [37.7](/filings/0001628280-26-038115.md) | [42.9](/filings/0001628280-26-053446.md) |
| Current assets | $m | [270](/filings/0001628280-23-037841.md) | [287](/filings/0001628280-24-003730.md) | [242](/filings/0001628280-25-031628.md) | [253](/filings/0001628280-24-035686.md) | [244](/filings/0001628280-24-045815.md) | [254](/filings/0001628280-25-004090.md) | [243](/filings/0001628280-26-038115.md) | [260](/filings/0001628280-25-037888.md) | [269](/filings/0001628280-25-048946.md) | [318](/filings/0001628280-26-005047.md) | [312](/filings/0001628280-26-053446.md) | [333](/filings/0001628280-26-053446.md) |
| Total assets | $m | [1,091](/filings/0001628280-23-037841.md) | [1,107](/filings/0001628280-24-003730.md) | [866](/filings/0001628280-25-031628.md) | [860](/filings/0001628280-24-035686.md) | [844](/filings/0001628280-24-045815.md) | [840](/filings/0001628280-25-004090.md) | [813](/filings/0001628280-26-038115.md) | [818](/filings/0001628280-25-037888.md) | [819](/filings/0001628280-25-048946.md) | [858](/filings/0001628280-26-005047.md) | [842](/filings/0001628280-26-053446.md) | [843](/filings/0001628280-26-053446.md) |
| Current liabilities | $m | [245](/filings/0001628280-23-037841.md) | [269](/filings/0001628280-24-003730.md) | [236](/filings/0001628280-25-031628.md) | [240](/filings/0001628280-24-035686.md) | [224](/filings/0001628280-24-045815.md) | [240](/filings/0001628280-25-004090.md) | [223](/filings/0001628280-26-038115.md) | [238](/filings/0001628280-25-037888.md) | [245](/filings/0001628280-25-048946.md) | [288](/filings/0001628280-26-005047.md) | [265](/filings/0001628280-26-053446.md) | [277](/filings/0001628280-26-053446.md) |
| Total liabilities | $m | [643](/filings/0001628280-23-037841.md) | [661](/filings/0001628280-24-003730.md) | [652](/filings/0001628280-25-031628.md) | [664](/filings/0001628280-24-035686.md) | [662](/filings/0001628280-24-045815.md) | [676](/filings/0001628280-25-004090.md) | [659](/filings/0001628280-26-038115.md) | [666](/filings/0001628280-25-037888.md) | [671](/filings/0001628280-25-048946.md) | [664](/filings/0001628280-26-005047.md) | [641](/filings/0001628280-26-053446.md) | [653](/filings/0001628280-26-053446.md) |
| Long-term debt | $m | [384](/filings/0001628280-23-037841.md) | [374](/filings/0001628280-24-003730.md) | [383](/filings/0001628280-25-031628.md) | [394](/filings/0001628280-24-035686.md) | [408](/filings/0001628280-24-045815.md) | [408](/filings/0001628280-25-004090.md) | [409](/filings/0001628280-26-038115.md) | [401](/filings/0001628280-25-037888.md) | [394](/filings/0001628280-25-048946.md) | [350](/filings/0001628280-26-005047.md) | [354](/filings/0001628280-26-053446.md) | [343](/filings/0001628280-26-053446.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001628280-26-038115.md) | not reported | [2.7](/filings/0001628280-25-048946.md) | [4.7](/filings/0001628280-26-005047.md) | [7.0](/filings/0001628280-26-053446.md) | [9.4](/filings/0001628280-26-053446.md) |
| Shareholders' equity | $m | [448](/filings/0001628280-23-037841.md) | [446](/filings/0001628280-24-003730.md) | [214](/filings/0001628280-25-031628.md) | [196](/filings/0001628280-24-035686.md) | [182](/filings/0001628280-24-045815.md) | [164](/filings/0001628280-25-004090.md) | [162](/filings/0001628280-26-053446.md) | [160](/filings/0001628280-26-053446.md) | [148](/filings/0001628280-25-048946.md) | [195](/filings/0001628280-26-005047.md) | [200](/filings/0001628280-26-053446.md) | [191](/filings/0001628280-26-053446.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [27.5 d](/filings/0001628280-24-045815.md) | [11.7 d](/filings/0001628280-25-004090.md) | [(11.8) d](/filings/0001628280-26-038115.md) | [(1.4)](/filings/0001628280-25-037888.md) | [(8.7) d](/filings/0001628280-25-048946.md) | [10.4 d](/filings/0001628280-26-005047.md) | [11.5 d](/filings/0001628280-26-038115.md) | [8.8](/filings/0001628280-26-053446.md) | [14.5 d](/filings/0001628280-25-048946.md) | [14.2 d](/filings/0001628280-26-005047.md) | [4.4 d](/filings/0001628280-26-038115.md) | [17.9](/filings/0001628280-26-053446.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [7.6](/filings/0001628280-26-053446.md) | not reported | not reported | not reported | [6.7](/filings/0001628280-26-053446.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2023 (2022-09-30) | Q3 FY2023 (2022-12-31) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [103](/filings/0001628280-23-037841.md) | [103](/filings/0001628280-24-003730.md) | [99.9](/filings/0001628280-24-035686.md) | [101](/filings/0001628280-24-045815.md) | [101](/filings/0001628280-25-004090.md) | [102](/filings/0001628280-25-037888.md) | [103](/filings/0001628280-25-048946.md) | [104](/filings/0001628280-26-005047.md) | [107](/filings/0001628280-26-053446.md) | [109](/filings/0001628280-25-048946.md) | [120](/filings/0001628280-26-005047.md) | [121](/filings/0001628280-26-053446.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 121,016,250 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001628280-26-053446.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:22 ET. No prices; not investment advice.